Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of apatinib for non-operative esophageal carcinoma
ChiCTR1900025060Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in esophageal cancer, sponsored by Shandong Cancer Hospital. Primary endpoints: overall survival, progression-free survival and 2 more. Started Aug 2019; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR1900025060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025060.